Granulocyte-Macrophage Colony-Stimulating Factor as a Therapeutic Target in Multiple Sclerosis

• Main Authors: Jehan Aram, Anna Francis, Radu Tanasescu, Cris S. Constantinescu
• Format: Article
• Language: English
• Published: Adis, Springer Healthcare 2018-12-01
• Series: Neurology and Therapy
• Subjects: Granulocyte-macrophage colony-stimulating factor; Experimental autoimmune encephalomyelitis; Multiple sclerosis
• Online Access: http://link.springer.com/article/10.1007/s40120-018-0120-1

Abstract Multiple sclerosis is an inflammatory neurodegenerative disease of the central nervous system (CNS) and the most frequent cause of non-traumatic disability in adults in the Western world. Currently, several drugs have been approved for the treatment of multiple sclerosis. While the newer drugs are more effective, they have less favourable safety profiles. Thus, there is a need to identify new targets for effective and safe therapies, particularly in patients with progressive disease for whom no treatments are available. One such target is granulocyte-macrophage colony-stimulating factor (GM-CSF) or its receptor. In this article we review data on the potential role of GM-CSF and GM-CSF inhibition in MS. We discuss the expression and function of GM-CSF and its receptor in the CNS, as well as data from animal studies and clinical trials in MS.